Personalized genomics involves analysing an individual's DNA to understand their genetic predispositions and assist in leading a healthy lifestyle. It enables the prediction of risks for various diseases like cancer, diabetes and heart disease. This allows for early detection and preventive healthcare measures like lifestyle modifications, regular health checkups and targeted screening.

The global Personalized Genomics Market is estimated to be valued at US$ 9.14 Bn in 2024 and is expected to exhibit a CAGR of 0.0% over the forecast period 2024 to 2031, as highlighted in a new report published by Coherent Market Insights.

Market Opportunity:
The opportunity for disease prevention through personalized genomics is driving its growth. Understanding one's genetic risks and familial history allows for lifestyle customization aiming to minimize risks. This includes following diets suitable to genetics, avoiding tobacco and excessive alcohol, monitoring vitals regularly and screening for high-risk diseases periodically. Regular physical activity and stress management according to individual needs can also avert future health issues. Personalized medicine facilitated by genomics provides a personalized roadmap for wellness which empowers people to take charge of their health proactively. This promise of disease prevention and delaying aging has increased adoption of personalized genomic services.

Porter's Analysis
Threat of new entrants: The threat of new entrants in the personalized genomics market is moderate. While start-ups can disrupt the market, established players have significant resources to invest in R&D and expanding their product portfolios.
Bargaining power of buyers: The bargaining power of buyers is high due to the availability of several genomics companies offering similar products and services. Buyers can negotiate on price and switch between brands.
Bargaining power of suppliers: There are a limited number of suppliers for raw materials and components used in genomic tests. This gives them moderate bargaining power over companies.
Threat of new substitutes: Substitutes include traditional healthcare diagnostic methods. However, the threat is low as personalized genomics offers more accurate health insights than conventional tests.
Competitive rivalry: The personalized genomics market sees high competition due to the presence of global industry leaders. Companies compete on technology, service quality, and customer experience.

SWOT Analysis
Strengths: Personalized genomics can deliver tailored medical treatment plans and preventive care strategies. It also provides family health history insights.
Weaknesses: High costs of tests and lack of insurance coverage. Accuracy and reliability challenges also exist as sequencing technologies are still evolving.
Opportunities: Growing awareness about genomics, rising chronic diseases, and advancements in cloud computing and AI present opportunities for market growth.
Threats: Ethical issues around data privacy and security. Regulatory uncertainty in some regions also poses a threat.

Key Takeaways

Global Personalized Genomics Market Demand is expected to witness high growth over the forecast period of 2024 to 2031.

Regional analysis: North America holds the major share of the personalized genomics market currently owing to the presence of leading genomics companies, favorable regulatory environment, and growing awareness among individuals. Asia Pacific is expected to be the fastest growing region during the forecast period with China and India emerging as key hubs for genomics research and development.

Key players: Key players operating in the personalized genomics market are Ancestry, Color Genomics, Editas Medicine, Helix, Illumina, Intellia Therapeutics, and Thermo Fisher Scientific. 23andMe also offers direct-to-consumer genotyping and DNA testing services.

Get More Insights on this Topic- https://www.marketwebjournal.com/personalized-genomics-market-value-outlook/